Trial
NCT04291703
STOP-T1D Low-Dose (ATG)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators
—
Condition
Diabetes Mellitus, Type 1
Intervention
Antithymocyte Globulin
Why stopped
Study terminated early due to low enrollment and lack of feasibility to meet target enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-07